Compare · DXCM vs GUTS
DXCM vs GUTS
Side-by-side comparison of DexCom Inc. (DXCM) and Fractyl Health Inc. (GUTS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and GUTS operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $33.10B, about 599.8x GUTS ($55.2M).
- Both names hit the wire about 6 times in the past 4 weeks.
- DXCM has more recent analyst coverage (25 ratings vs 6 for GUTS).
- Company
- DexCom Inc.
- Fractyl Health Inc.
- Price
- -
- -
- Market cap
- $33.10B
- $55.2M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2024
- News (4w)
- 6
- 6
- Recent ratings
- 25
- 6
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest DXCM
- Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin
- Barclays initiated coverage on Dexcom with a new price target
- Dexcom Schedules Third Quarter 2026 Earnings Release and Conference Call for October 29, 2026 at 4:30 p.m. Eastern Time
- Dexcom U Enters Season 5 With a Record Roster and Evidence That Diabetes Stigma Among Young Athletes Is Fading
- EVP Chief People & Culture Off Stern Sadie sold $220,975 worth of shares (2,565 units at $86.15) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 123,478 units (SEC Form 4)
- Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care
- EVP Chief Legal Compliance Off Brown Michael Jon sold $142,868 worth of shares (1,700 units at $84.04) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 99,885 units (SEC Form 4)
- Director Augustinos Nicholas sold $679,769 worth of shares (8,089 units at $84.04) as part of a pre-agreed trading plan (SEC Form 4)
- DexCom Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Dexcom Promotes Jereme Sylvain to Chief Operating Officer
Latest GUTS
- GUTS UPCOMING DEADLINE: Levi & Korsinsky Alerts Fractyl Health, Inc. Stockholders of Securities Class Action - Contact the Firm
- SEC Form 8-K filed by Fractyl Health Inc.
- Fractyl Health's Revita Meets Six-Month Co-Primary Endpoint in Ongoing REMAIN-1 Pivotal Study, With Highly Statistically Significant Reduction in Weight Regain After GLP-1 Discontinuation
- GUTS Shareholder Alert: Fractyl Health, Inc. Securities Class Action Lawsuit - Investors Should Contact Levi & Korsinsky
- GUTS DEADLINE: Levi & Korsinsky Reminds Fractyl Health, Inc. Investors of Upcoming Securities Class Action Deadline
- Fractyl Health Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- Fractyl Health Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Bradley William bought $39,903 worth of shares (64,516 units at $0.62), increasing direct ownership by 76% to 149,138 units (SEC Form 4)
- Fractyl Health Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Fractyl Health to Participate in Upcoming September Investor Conferences